<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331627</url>
  </required_header>
  <id_info>
    <org_study_id>2017-000242-22</org_study_id>
    <nct_id>NCT03331627</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL</brief_title>
  <official_title>A Phase III Multicenter, Double-blind, Placebo-controlled, Study Evaluating the Safety, and Efficacy of STR001 Treatment in Adults With Sudden Sensorineural Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Strekin AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Strekin AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      a multicenter, double-blind, placebo-controlled study in patients with Sudden Sensorineural
      Hearing Loss (SSHL). Patients will be treated with STR001 thermogel (STR001-IT) / STR001
      tablets (STR001-ER) and corresponding Placebo on top of standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 24, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>intratympanic gel injection followed by 12 weeks oral treatment
intratympanic gel injection followed by 12 weeks oral treatment placebo
intratympanic gel injection placebo followed by 12 weeks oral treatment placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute hearing improvement after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absolute hearing improvement after 12 weeks measured with PTA using the mean value of the 3 most affected contiguous baseline frequencies (dB)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete hearing recovery after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentages of patients with complete hearing recovery after 12 weeks measured with PTA using the mean value of the 3 most affected contiguous frequencies at baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Acute Hearing Loss</condition>
  <arm_group>
    <arm_group_label>STR001-IT/STR001-ER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>STR001-IT/STR001-ER Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>STR001-IT placebo/STR001- ER placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR001-IT and STR001-ER</intervention_name>
    <description>STR001-IT intrataympanic injection and STR001-ER tablet</description>
    <arm_group_label>STR001-IT/STR001-ER</arm_group_label>
    <arm_group_label>STR001-IT/STR001-ER Placebo</arm_group_label>
    <arm_group_label>STR001-IT placebo/STR001- ER placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged ≥ 18

          2. Patients with a SSHL within 96 hours of its perception

          3. Sudden Sensorineural Hearing Loss including

               1. idiopathic unilateral Sudden Sensorineural Hearing Loss or

               2. acute uni- or bilateral acoustic trauma-induced Sudden Sensorineural Hearing Loss

        Exclusion Criteria:

          1. Patients with a history of Meniere's Disease

          2. Patients with a hearing threshold above 100 dB across at least 6 frequencies

          3. Patients with endolymphatic, hydrops or history of fluctuating hearing loss

          4. Patients with suspected perilymph fistula, membrane rupture, retrocochlear lesions or
             a barotrauma

          5. Patients with an air-bone gap of ≥ 20 dB in 3 contiguous frequencies at baseline

          6. Previous SSHL incident at the same ear

          7. Patients with acute or chronic otitis media or otitis externa.

          8. Patients with congenital hearing loss

          9. Patients with known hypersensitivity to pioglitazone, other thiazolidindiones or any
             formulation component

         10. Use of thiazolidinedione (e.g. pioglitazone, rosiglitazone) in the last 6 months prior
             to baseline

         11. Any use of CYP450 2C8 inducers (e.g. rifampicine)

         12. Fibrates (e.g. gemfibrozil, fenofibrate) in the last 6 months prior to baseline

         13. Patients where oral administration of pioglitazone is contraindicated (i.e. cardiac
             failure or history of cardiac failure (NYHA stages I to IV), hepatic impairment,
             diabetic ketoacidosis, current bladder cancer or a history of bladder cancer,
             uninvestigated macroscopic haematuria

         14. Women who are breastfeeding, pregnant or plan to get pregnant during the trial
             duration

         15. Women of childbearing potential unwilling or unable to practice effective method of
             contraception

         16. Participation in other clinical trials in the last month prior to baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Strekin AG</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktor Chrobok</last_name>
      <phone>+420 495 833 790</phone>
      <email>chrobok@fnhk.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Arndt</last_name>
      <phone>0049 761 270 42120</phone>
      <email>susan.arndt@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Kleinjung</last_name>
      <phone>004144 255 5900</phone>
      <email>Tobias.Kleinjung@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

